| GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, and other serious medical conditions. GTx is developing enobosarm (Ostarine®;GTx-024), a selective androgen receptor modulator or SARM, for the prevention and treatment of muscle loss in patients with non-small cell lung cancer and for other muscle wasting diseases. GTx is also developing Capesaris® (GTx-758), a selective ER alpha agonist, as a hormonal therapy for men with advanced prostate cancer. |
|  | |
|
|
| Date | Title | | | 05/03/13 | GTx Provides Corporate Update and Reports First Quarter 2013 Financial Results| MEMPHIS, Tenn.--(BUSINESS WIRE)--May. 3, 2013--
GTx, Inc. (Nasdaq: GTXI) today provided a Company update and reported
financial results for the first quarter of 2013.
“We expect the last patients to complete our two pivotal Phase 3
clinical studies of enobosarm to prevent and treat muscle wasting in
non-small cell lung cancer by the end of this month, which should allow
us to release topline data from the studies in the third quarter of this
... |
|  | | 04/30/13 | GTx Initiating Phase 2, Open-Label Study of Enobosarm to Treat ER Positive Metastatic Breast Cancer| MEMPHIS, Tenn.--(BUSINESS WIRE)--Apr. 30, 2013--
GTx, Inc. (Nasdaq: GTXI), announced today that it is initiating a proof
of concept, Phase 2, open-label clinical study to evaluate enobosarm
(GTx-024), a selective androgen receptor modulator (SARM), for the
potential treatment of metastatic breast cancer.
“We know from prior studies that women with hormone receptor positive
metastatic breast cancer which has progressed following treatment with
... |
| | | 04/19/13 | GTx, Inc. To Host First Quarter 2013 Financial Results Conference Call and Webcast| MEMPHIS, Tenn.--(BUSINESS WIRE)--Apr. 19, 2013--
GTx, Inc. (NASDAQ: GTXI) today announced that it will host a conference
call and webcast to provide a corporate update and discuss the Company's
first quarter 2013 financial results on Friday, May 3 at 9:00 a.m.
Eastern Time. The call and webcast will follow the release of the
financial results earlier that day.
To listen to the conference call, please dial:
866-953-6857 fr... |
| | | 04/15/13 | GTx's Phase III Clinical Studies of Enobosarm (GTx-024) to Continue as Planned Following Planned Safety Review| MEMPHIS, Tenn.--(BUSINESS WIRE)--Apr. 15, 2013--
GTx, Inc. (Nasdaq: GTXI) today announced that a per protocol safety
review of unblinded safety data on Friday April 12, 2013, by an
independent Data Safety Monitoring Board (DSMB), resulted in a
determination that GTx continue as planned its two pivotal Phase III
clinical trials of enobosarm (GTx-024) for the prevention and treatment
of muscle wasting in patients with advanced non-small cell lung cancer.
... |
| |
|
|
| Transfer Agent | Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
Phone: 877-282-1168
Fax: 781.575.2500
Corporate Website: http://www.computershare.com
|
| | Legal Counsel |
Cooley Godward Kronish LLP
5 Palo Alto Square
3000 El Camino Real
Palo Alto, CA 94306
Phone: 650.843.5000
Fax: 650.849.7400
Corporate Website: www.cooley.com |
| | Local Corporate Counsel | Bass, Berry & Sims, PLC
100 Peabody Avenue
Suite 900
Memphis, TN 38103
Phone: 901.543.5900
Fax: 901.543.5999
Corporate Website: http://www.bassberry.com
|
| | Accountants | Ernst & Young LLP
6410 Poplar Avenue
Suite 500
Memphis, TN 38119
Phone: 901.526.1000
Fax: 901.543.5999
Corporate Website: http://www.ey.com
|
|
|
Print Page
E-mail Page
RSS Feeds
E-mail Alerts
IR Contacts
Financial Tear Sheet
